Resource Summary Report

Generated by RRID on Aug 4, 2026

YAP Antibody

RRID:AB_2218911
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4912, RRID:AB_2218911

Antibody Information

URL: http://antibodyregistry.org/AB_2218911

Proper Citation: Cell Signaling Technology Cat# 4912, RRID:AB_2218911

Target Antigen: YAP

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IHC-P. Consolidation: AB_10694682.

Antibody Name: YAP Antibody

Description: This polyclonal targets YAP

Target Organism: monkey, rat, mouse, human

Defining Citation: PMID:28486106

Antibody ID: AB_2218911

Vendor: Cell Signaling Technology

Catalog Number: 4912

Alternative Catalog Numbers: 4912S

Record Creation Time: 20250820T044247+0000

Record Last Update: 20250820T194335+0000

Ratings and Alerts

No rating or validation information has been found for YAP Antibody.

No alerts have been found for YAP Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 59 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Guo W, et al. (2025) Mitochondrial CCN1 drives ferroptosis via fatty acid ?-oxidation. Developmental cell, 60(17), 2294.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. Cancer cell.

Li G, et al. (2025) Microenvironmental ?-TrCP negates amino acid transport to trigger CD8+ T cell exhaustion in human non-small cell lung cancer. Cell reports, 44(1), 115128.

Weaver MR, et al. (2025) The STRIPAK complex is required for radial sorting and laminin receptor expression in Schwann cells. Cell reports, 44(3), 115401.

Li S, et al. (2025) Glutamine synthetase modulates YAP activation by stabilizing LATS under glutamine homeostasis. Cell reports, 44(12), 116620.

Hu DJ, et al. (2025) Non-canonical Wnt signaling promotes epithelial fluidization in the repairing airway. Nature communications, 16(1), 4124.

Hsu HE, et al. (2025) Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures. Molecular systems biology, 21(11), 1547.

McKenna CF, et al. (2024) Postabsorptive and postprandial myofibrillar protein synthesis rates at rest and after resistance exercise in women with postmenopause. Journal of applied physiology (Bethesda, Md. : 1985), 136(6), 1388.

Hung CH, et al. (2024) Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer. Nature communications, 15(1), 7885.

Naderi Yeganeh P, et al. (2024) Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer's disease. Neuron.

Meyer NP, et al. (2024) Arp2/3 complex activity enables nuclear YAP for naïve pluripotency of human embryonic stem cells. eLife, 13.

Shiraishi K, et al. (2023) Biophysical forces mediated by respiration maintain lung alveolar epithelial cell fate. Cell, 186(7), 1478.

Ouyang H, et al. (2023) p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP. Cell reports, 42(12), 113486.

Chen L, et al. (2023) TGFB1 induces fetal reprogramming and enhances intestinal regeneration. Cell stem cell, 30(11), 1520.

Edwards W, et al. (2023) Quantitative proteomic profiling identifies global protein network dynamics in murine embryonic heart development. Developmental cell, 58(12), 1087.

Khampang S, et al. (2023) CRISPR/Cas9 mediated approach to generate YAP-depleted human embryonic stem cell line (MUSIe002-A-1). Stem cell research, 66, 102990.

Park S, et al. (2022) Transcription factors TEAD2 and E2A globally repress acetyl-CoA synthesis to promote tumorigenesis. Molecular cell, 82(22), 4246.

Guo Y, et al. (2022) Opposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity. Cell reports, 41(1), 111452.

Kim M, et al. (2022) YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Developmental cell, 57(2), 212.

Elamin YY, et al. (2022) Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer cell, 40(7), 754.